Single-Dose Nirsevimab Prophylaxis for Season-Long RSV Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for effective passive immunization against Respiratory Syncytial Virus (RSV) infections in infants, particularly for healthy preterm and term infants, as current vaccines and prophylaxis are limited in efficacy and accessibility, and existing treatments lack a single-dose solution that provides prolonged protection throughout RSV seasons.

Innovation Solution

Administration of a single dose of nirsevimab before or outside the RSV season, which offers protection against RSV lower respiratory tract infections for more than five months, potentially up to twelve months, through intramuscular injection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If palivizumab is administered monthly throughout the RSV season, then protection against RSV infection is maintained, but the treatment complexity and accessibility are limited due to multiple dosing requirements

Engineering Contradiction:

Improveprotection against RSV infectionVSAvoiddosing regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines multiple monthly palivizumab doses into a single nirsevimab dose that provides equivalent or superior protection throughout the entire RSV season, eliminating the need for repeated administrations and simplifying the treatment protocol

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

Nirsevimab is administered as a single preliminary dose before the RSV season begins, providing prolonged protection that covers the entire season without requiring additional doses during the season, unlike monthly palivizumab administration

Inventive Principle:

Principle #10Preliminary action

2Productivity

If palivizumab is administered to high-risk children only, then resource allocation is optimized, but healthy preterm and term infants remain unprotected despite their vulnerability to severe RSV LRTI

Engineering Contradiction:

Improveresource allocation efficiencyVSAvoidprotection coverage

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

Nirsevimab is developed as a universal prophylactic that can be administered to all infants regardless of risk status, unlike palivizumab which is restricted to high-risk children, thereby extending protection to healthy preterm and term infants who also face significant RSV vulnerability

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Duration of action of moving object

If RSV season duration is extended to five months or longer, then the window for infection risk increases, but monthly dosing of palivizumab becomes less accessible and more burdensome

Engineering Contradiction:

ImproveRSV season durationVSAvoiddosing accessibility

Core Design Contradiction:

Duration of action of moving objectVSEase of operation

Solution Approach 1:

The patent consolidates the protection needed for extended RSV seasons (5-10 months) into a single nirsevimab administration, eliminating the burden of monthly dosing while maintaining continuous protection throughout the extended seasonal window

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20250340622A1Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab

Publication Date: 2025.11.06 MEDIMMUNE LTD

AI summary

The present disclosure provides methods of preventing, reducing the risk, or mitigating RSV lower respiratory tract infection by administering nirsevimab.